What PRN medication is appropriate for managing acute aggression in an older adult (≥ 65 years)?

Oral Quetiapine is the Safest PRN Medication for Geriatric Aggression

For acute aggression in older adults ≥65 years, oral quetiapine should be your first-line PRN medication based on the best available safety data, with oral formulations strongly preferred over parenteral routes. 1

Key Recommendation Framework

The 2025 Geriatric Emergency Department Guidelines systematic review provides the most current, high-quality evidence specifically addressing this population. Oral medications, particularly quetiapine, demonstrated the best safety profile among all reported medications for severe agitation in older adults. 1

Medication Selection Algorithm

First-line PRN:

• Oral quetiapine - Best safety profile overall 1
• Start low, go slow with dosing
• Monitor for dose-dependent adverse events (though less pronounced than other agents) 1

Avoid entirely:

• Midazolam - Elevated risk of serious adverse events without efficacy gains 1
• Escalating doses of lorazepam - Increased adverse event risk with higher doses 1

Use with extreme caution if oral route impossible:

• Parenteral formulations (IM/IV) significantly increase adverse event risk compared to oral administration 1
• If parenteral route necessary, avoid droperidol at high doses due to dose-response signal for adverse events 1

Critical Safety Considerations

The evidence reveals sobering statistics: serious adverse events occurred in 16.8% of older adults who received antipsychotic or anxiolytic medications for agitation 1. These include:

• Respiratory depression (apnea, desaturation <90%, intubation)
• Cardiac complications (QTc prolongation >500ms, arrhythmias, hypotension)
• Dystonia and falls
• Delirium exacerbation
• Cardiac arrest and mortality 1

Route of Administration Matters

The route of administration is as important as the medication choice itself. Intravenous and intramuscular administration substantially increases adverse drug event risk compared to oral routes 1. This finding challenges traditional emergency practice patterns where parenteral routes are often reflexively chosen for rapid effect.

Common Pitfalls to Avoid

1. Don't default to benzodiazepines - Despite historical practice patterns, midazolam poses unacceptable risk 1, and lorazepam shows dose-dependent toxicity 1

2. Don't assume parenteral = better - The perceived need for rapid onset doesn't justify the significantly elevated safety risks of IM/IV routes 1

3. Don't ignore nonpharmacologic approaches first - Person-centered communication and sensory therapy should always precede medication 1, though this question specifically addresses PRN medication selection

4. Don't use standard adult dosing - Older adults have altered pharmacokinetics and increased sensitivity to adverse effects 2

Clinical Context Nuances

The underlying etiology matters but often isn't immediately clear. The differential includes:

• Hyperactive delirium
• Intoxication
• Behavioral/psychiatric symptoms of dementia
• Primary psychosis 1

However, when facing severe, undifferentiated agitation requiring immediate pharmacologic intervention, oral quetiapine remains the safest empiric choice while diagnostic workup proceeds 1.

Supporting Evidence for Alternative Agents

If quetiapine is contraindicated or unavailable, a 2022 review recommended olanzapine as first-line for intramuscular use due to its lower adverse effect profile compared to other parenteral options 3. However, remember that any parenteral route increases risk compared to oral administration 1.

For dementia-related agitation specifically, recent 2026 consensus identified brexpiprazole as having the strongest evidence and most favorable safety profile among approved agents, with risperidone and aripiprazole as alternatives requiring careful cerebrovascular monitoring 4. However, these recommendations address chronic management rather than acute PRN use.

Monitoring Requirements

After PRN administration, monitor for:

• Oxygen saturation (target ≥95%)
• Blood pressure (hypotension risk)
• QTc interval if baseline prolongation or cardiac risk factors
• Mental status (paradoxical worsening of delirium)
• Extrapyramidal symptoms 1

Document the indication, dose, response, and any adverse effects meticulously - studies show complete documentation occurs in only 27.8% of agitation encounters 2, representing a significant quality gap.